Clinical trial
Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune…
NCT00175435 · University of British Columbia, Other · Completed
Key facts
| NCT number | NCT00175435 |
|---|---|
| Title | Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator |
| Official title | Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator |
| Lead sponsor | University of British Columbia, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Resiquimod gel |
| Enrollment | 39 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 2, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: